{
    "title": "Roche: Tecentriq cocktail slows kidney cancer progression",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-5166377/Roche-Tecentriq-cocktail-slows-kidney-cancer-progression.html",
    "date": "2017-12-11",
    "keywords": [
        "cancer",
        "combination",
        "treatment",
        "kidney",
        "tecentriq",
        "roche",
        "avastin",
        "competition",
        "opdivo",
        "risk",
        "death",
        "trial",
        "care",
        "cocktail",
        "immune",
        "system",
        "percent",
        "yervoy",
        "holford",
        "benefit",
        "miller",
        "immunotherapy",
        "drug",
        "disease",
        "drugmaker",
        "monday",
        "standard",
        "renal",
        "cell",
        "result",
        "week",
        "progression",
        "lung",
        "merck",
        "co",
        "inc",
        "plan",
        "revenue",
        "trio",
        "herceptin",
        "rituxan",
        "consequence",
        "body",
        "evidence",
        "rationale",
        "horning",
        "officer",
        "potential",
        "gmt",
        "line",
        "health",
        "index",
        "doubt",
        "tecentriqs",
        "study",
        "market",
        "fight",
        "comparison",
        "september",
        "group",
        "bar",
        "analyst",
        "jeffrey",
        "note",
        "presentation",
        "conference",
        "magnitude",
        "confirmation",
        "buy",
        "rating",
        "michael"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}